Travis van Meter, MD
Vascular & Interventional Radiology · Dallas, TXNPI 1750339461
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Sirtex Medical Inc accounts for 60.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $8,927 and has fallen 87.7% since, to $1,101 in 2025.
Across 394 payments — averaging $83.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$20K
- Boston Scientific$6K
- Embolx, Inc.$2K
- Cook Medical LLC$1K
- Delcath Systems$786
- Medtronic$474
- plus $3K from 24 others
Across 5 payments — averaging $1521.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$8K
What the payments were for
- Consulting fees$5,00015%
- Speaking & faculty fees$12,00037%
- Travel & lodging$2,2437%
- Food & beverage$13,62641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sirtex Medical Inc | 185 | $19,740 |
| Boston Scientific | 69 | $5,910 |
| Embolx, Inc. | 1 | $1,600 |
| Cook Medical LLC | 42 | $1,071 |
| Delcath Systems | 2 | $786 |
| Medtronic(2 entities) | 12 | $474 |
| Angiodynamics, Inc. | 6 | $448 |
| Cardiovascular Systems Inc. | 14 | $439 |
| Isoray, Inc | 1 | $400 |
| Abbott | 12 | $294 |
| Stryker(2 entities) | 4 | $235 |
| Integra Lifesciences Corporation | 2 | $177 |
| Johnson & Johnson | 15 | $146 |
| Davol Inc. | 1 | $136 |
| Ipsen Biopharmaceuticals, Inc | 1 | $124 |
| Nevro Corp. | 3 | $103 |
| AstraZeneca | 1 | $96 |
| Shockwave Medical, Inc | 2 | $93 |
| AbbVie | 1 | $86 |
| Covidien LP | 1 | $84 |
| Inari Medical, Inc. | 4 | $82 |
| Trisalus Life Sciences, Inc. | 2 | $74 |
| Philips North America LLC | 2 | $61 |
| Terumo Medical Corporation | 3 | $52 |
| Bard Peripheral Vascular, Inc. | 2 | $49 |
| W. L. Gore & Associates, Inc. | 2 | $46 |
| Tactile Systems Technology Inc | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Surmodics, Inc. | 1 | $15 |
| Reflow Medical Inc | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$16,902
- GENERAL VASCULAR INTERVENTION$3,125
- GENERAL - THERAPIES$1,119
- Hepzato Kit$786
- Brachytherapy Source$400
- SALVATION$154
- TheraSphere Y90 Glass Microspheres 10 GBq$145
- PHASIX$136
- ONIVYDE$124
- DIREXION$123
- Diamondback Peripheral$121
- CODMAN CERTAS$111
- CUSA CLARITY$111
- CODMAN HAKIM$111
- DURASEAL EXACT SPINAL SEALANT SYSTEM$111
- Cook Medical Zilver PTX$105
- OSTEOCOOL RF ABLATION$102
- Auryon Laser System 100-120 Vac$101
How this compares
$32,868 in reported general payments places this provider in the 85th percentile of 299 vascular & interventional radiology providers in Texas.
See all vascular & interventional radiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $6,473 |
| Ondansetron Hcl | 53 | $1,077 |
| Sucralfate | 56 | $799 |
| Methylprednisolone | 79 | $543 |
| Omeprazole | 71 | $443 |
| ClopidogrelClopidogrel Bisulfate | 20 | $246 |
| Metoclopramide Hcl | 62 | $194 |
| Ciprofloxacin Hcl | 18 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $146 | $6,47312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 299 vascular & interventional radiology providers in Texas.
Other vascular & interventional radiology in Dallas
- Sanjeeva KalvaDallas$128K
- Aaron FrittsDallas$101K
- Dev BatraDallas$72K
- Stephen HumphreyDallas$63K
- Steve HongDallas$28K
- Seung KimDallas$22K
- Glenn PrideDallas$17K
- Orlando DiazHouston$611K
- Rahul ShethHouston$410K
- Miguel MonteroHouston$386K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.